Summary of minutes of EUCAST Steering Committee Meeting  
Copenhagen, Denmark, 8-9 July 2013

Attending
Dr Derek F.J. Brown  DB  Scientific Secretary  United Kingdom
Dr Rafael Cantón  RC  Chairperson  Spain
Prof Luc Dubruel  LD  CA-SFM  France
Dr Christian Giske  CG  SRGA  Sweden
Prof Gunnar Kahlmeter  GK  Clinical Data Co-ordinator  Sweden
Prof Alasdair P. MacGowan  AM  BSAC  United Kingdom
Prof Luis Martinez-Martinez  LM  EUCAST General Committee  Spain
Prof Johan W. Mouton  JM  CRG  The Netherlands
Prof Sören Gatermann  SG  EUCAST General Committee  Germany
Dr Martin Steinbakk  MS  NWGA  Norway

Apologies
Dr Robert Skov  RS  EUCAST General Committee  Denmark

1 Chairman’s welcome SG was welcomed to his first meeting as General Committee representative.

2 Minutes of meeting of 30 April-1 May 2013 With minor corrections the minutes were accepted.

3 Matters arising from minutes of 30 April-1 May 2013 (items not covered by agenda) MIC distributions for N. gonorrhoeae from the Netherlands will be sent to EUCAST.

4 New agents
New antimycobacterial agent: The current position is with the agent is being assessed.

New cephalosporin: Proposed breakpoints are being discussed with the company.

Review of carbapenem breakpoints is in progress.

New antimycobacterial agent: Breakpoints have been agreed.

New glycopeptide agent: A preliminary presentation will be given at the next meeting.

New tetracycline: A preliminary presentation will be given at the next meeting.

5 EUCAST rationale documents A document for ceftaroline is being prepared. Update of other documents is being reviewed.

6 Subcommittees
Antifungal susceptibility testing: Members from countries with no representation on the committee are being sought.

Detection of resistance mechanisms of clinical and/or epidemiological importance: An updated document will be sent for wide consultation in the near future.

7 Breakpoint issues
Breakpoint tables version 4.0 is being prepared.

Agreed to include ciprofloxacin and levofloxacin breakpoints (S ≤ 4 mg/L and R > 4 mg/L) for enterococci causing uncomplicated UTI.

Neisseria meningitidis breakpoints for benzylpenicillin and ciprofloxacin are being discussed.

Agreed to wide consultation on proposal amoxicillin-clavulanic acid breakpoints of S ≤32 mg/L, R >32 mg/L for Enterobacteriaceae from uncomplicated UTI only.

Proposals for sulbactam breakpoints for Acinetobacter spp. are being considered.
The joint EUCAST-CLSI review of colistin breakpoints is continuing. An international conference on polymyxins was held in Prato, Italy in May 2013.

Gentamicin breakpoints splitting the wild type for *S. aureus* are being reviewed.

The Australian NAC are to register exceptions to the EUCAST breakpoints for cefuroxime axetil and *H. influenzae* and for cefazolin and Enterobacteriaceae.

Clinical data on use of trimethoprim and trimethoprim-sulfamethoxazole in UTI caused by *M. morganii* and *P. mirabilis* are being collected.

Data to support the suggestion that aminoglycosides and 1st/2nd generation cephalosporins should not be used for iv treatment of systemic infections with *Salmonella* and *Shigella* are being sought.

A separate line for fluoroquinolones and *Salmonella* and a note on screening for fluoroquinolone resistance with nalidixic acid will be added to breakpoint tables.

A note on testing for dissociated macrolide resistance will be sent for wide consultation.

A proposal to exclude *S. agalactiae* from breakpoints for flucloxacillin and other isoxazolylpenicillins has been sent for wide consultation.

A table of proposed breakpoints for topical agents has been sent for wide consultation.

Addition of EUCAST expert rules to breakpoint tables is being considered. The rules are due for review in 2014.

A note on fosfomycin disk diffusion testing will be added to breakpoint tables.

Data on disk diffusion tests for streptomycin high level resistance in enterococci will be reviewed.

Noted that in the absence of breakpoints for high level aminoglycoside resistance in viridans group streptococci breakpoints for enterococci are widely used.

The status of breakpoints for penicillins and *N. gonorrhoeae* is being reviewed as the agents are rarely used clinically for treatment of gonorrhoea.

Guidelines for manufacturers on data needed for development of breakpoints for new antimycobacterial agents are being considered.

### Organisms without EUCAST breakpoints

**Discussions on breakpoints for *Legionella* spp. are continuing.**

A guidance note on susceptibility testing of *Burkholderia cepacia* has been produced.

A guidance note on susceptibility testing of *Actinomyces* spp is being prepared.

Proposals for breakpoints for *Corynebacterium* spp. have been released for general consultation.

Breakpoints for *P. aeruginosa* are generally applicable to other *Pseudomonas* species and data will be reviewed to see whether minor modifications to disk diffusion breakpoints are necessary.

Breakpoints for *Kingella kingae* are being investigated.

### EUCAST methods

Studies are in progress on disk diffusion tests for new inhibitor combinations and for ceftaroline.

Collaborative studies are continuing to establish MIC-zone diameter correlations and control ranges with fixed inhibitor concentrations of amoxicillin-clavulanic acid and ampicillin-sulbactam.

As *H. influenzae* NCTC 8468 is not widely available, studies will be undertaken to replace it as a control strain with *H. influenzae* ATCC 49766.
| 10 | **Implementation of EUCAST breakpoints**  
    Progress on implementation continues to be monitored but it is difficult to get data from some countries. |
| 11 | **EUCAST MIC and zone diameter distribution website**  
    The clinical breakpoint columns will be removed from the tables as they are not required here, and the references to breakpoints in the histograms will be removed as they cause some confusion. |
| 12 | **Publications and presentations**  
    Draft papers on ECOFFs, reporting as found for Enterobacteriaceae and uptake of EUCAST breakpoints are being prepared. A paper on the EUCAST disk diffusion method has been submitted for publication. A list of EUCAST presentations is being maintained. |
| 13 | **NACs**  
    A NAC has been established in the USA. |
| 14 | **EUCAST SOPs**  
    Setting breakpoints for new agents (SOP 1.1): The revised version has been released.  
    Harmonisation of breakpoints for existing agents (SOP 2.1): A revised draft was approved.  
    EUCAST committees (SOP 4.1): A revised draft was approved.  
    EUCAST websites (SOP 6.0): The revised version has been released. |
| 15 | **ESCMID**  
    There will be a EUCAST educational workshop at ECCMID Barcelona in 2014.  
    There will be a joint EUCAST workshop with the PK/PD study group (EPASG) and ESGARS in Linz, Austria in September 2014. |
| 16 | **EMA**  
    No new information. |
| 17 | **CLSI**  
    A “Dose-dependent susceptible” category (in reports listed as S-DD) in place of intermediate will be introduced by CLSI for cefepime only. The EUCAST definition of intermediate allows for use of an agent when a higher dose can be given so there is no need for an S-DD category. |
| 18 | **ECDC**  
    Discussion on the proposal for an international MIC database and ECOFFs are continuing. |
| 19 | **Any other business**  
    Noted that viridans streptococci breakpoints should be used for viridans streptococci irrespective of whether they are positive for Lancefield groups A,B,C,G antigens. |
| 20 | **Next meetings**  
    25-26 November 2013, Brussels, Belgium.  
    10-11 February 2014, Munich, Germany.  
    13-14 May 2014, Barcelona, Spain (immediately following ECCMID).  
    15-16 September 2014, Linz, Austria (before ESCMID Postgraduate Workshop). |

Ratified summary of minutes of meeting 8-9 July 2013. Prepared by DB, RC and GK